Table 1.
Patient and procedural details (PUJ—pelviureteric junction, LP—lower pole, MP—mid pole, LP—lower pole, UA—uric acid, COM—Calcium oxalate monohydrate, COD—calcium oxalate dihydrate, CPC—calcium phosphate carbonate, CHP—calcium hydrogen phosphate dihydrate, MAH—magnesium ammonium phosphate).
| MOSES 60 W (Group A) | Holmium 20 W (Group B) | ||
|---|---|---|---|
| Number | 38 | 38 | |
| Age mean ± SD (range), years | 53.8 ± 5.8, (9–81) | 58.1 ± 14.5, (22–84) | p = 0.26 |
| Gender: Male:Female | 21 (55.3%): 17 (44.7%) | 25 (65.7%): 13 (34.3%) | p = 0.35 |
| Side: Left: Right: Bilateral | 21:16:1 | 22:15:1 | p = 0.97 |
| Location | p = 0.52 | ||
| Ureter | 11 | 11 | |
| PUJ:LP:MP:UP | 4:8:3:2 | 9:4:4:1 | |
| Multiple | 10 | 9 | |
| Single stone size (mm) Mean ±SD (range) |
10.9 ± 4.4 (4–24) |
11.8 ± 4.0 (4–20) |
p = 0.34 |
| Cumulative stone length (mm) Mean ±SD (range) |
15.5 ± 9.9 (4–57) | 16.5 ± 11.3 (5–58) |
p = 0.63 |
| Number of stones mean ±SD (range) |
2.0 ± 2.0 (1–11) | 1.8 ± 1.3 (1–7) |
p = 0.51 |
| Pre-op stent | 10 (26.3%) | 13 (34.2%) | p = 0.45 |
| Post-op stent | 33 (86.8%) | 37 (97.3%) | p = 0.20 |
| Ureteral access sheath | 22 (57.8%) | 21 (55.2%) | p = 0.82 |
| Operation time (min) mean± SD (range) | 51.6 ± 17.1 (16–90) | 82.1 ± 27.0 (40–160) | p ≤ 0.0001 |
| Initial Stone Free rate (SFR) | 37 (97.3%) | 31 (81.6%) | p = 0.05 |
| Final SFR | 38 (100%) | 37 (97.3%) | |
| Patients requiring 2nd procedure | 1 (2.6%) | 7 (18.4%) | p = 0.05 |
| Length of stay (LOS) (days) median (range) | 0 (0–2) | 0 (0–6) | p = 0.26 |
| Stone analysis | |||
| UA + COM | 3 | 1 | |
| COM | 15 | 7 | |
| COD + COM + CPC | 1 | 1 | |
| COD + CHP + COM | 2 | 1 | |
| COD + CPC | 3 | 1 | |
| COM + COD | 2 | 3 | |
| COM + CPC | 8 | 9 | |
| CPC + MAH | 1 | 6 | |
| Cystine | 2 | 2 | |
| UA | 0 | 1 | |
| Complications (%) | 2 (5.2%) | 5 (13.1%) | p = 0.43 |
| Pain | 2 | 0 | Clavien I |
| Urosepsis | 0 | 2 | Clavien II |
| UTI | 0 | 2 | Clavien II |
| Pyelonephritis | 0 | 1 | Clavien II |